Sign In
Buy ADC
$76.32
-0.590 (-0.767%)
At Close: Aug 04, 2026
2 Dividends That Are Strategically And Tactically Attractive For Retirement Investors
05:04pm, Tuesday, 01'st Oct 2024
For prudent retirement income seeking investors, securities that could be considered strategic fits should carry sound balance sheet, conservative cash flow profiles and at least above inflation-level
Agree Realty Announces Third Quarter 2024 Earnings Release Date and Conference Call Information
04:05pm, Tuesday, 01'st Oct 2024
ROYAL OAK, Mich. , Oct. 1, 2024 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that it will release its third quarter 2024 operating results after the market clos
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Tuesday, 01'st Oct 2024
LAUSANNE, Switzerland, Oct. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced
Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress
11:33pm, Saturday, 28'th Sep 2024
CHENGDU, China , Sept. 28, 2024 /PRNewswire/ -- From September 25 th to 29th, the 27th China Clinical Oncology Congress and the 2024 CSCO Annual Meeting were held in Xiamen.
4 Dividend Stocks Yielding 4% or More to Buy for Passive Income Right Now
04:19am, Tuesday, 24'th Sep 2024
Several companies currently offer dividend yields above 4%. They also have outstanding records of increasing their dividends.
Agree Realty: No Longer Undervalued, Still A Buy
09:43am, Monday, 23'rd Sep 2024
Agree Realty achieves industry-leading growth at a low cost of capital, making it a fundamentally strong business and a long-term buy. REITs are expected to perform well given the lower interest rate
Earn A Potential 7% Monthly Income By Owning These REITs
08:15am, Monday, 23'rd Sep 2024
REITs still offer high yields, in excess of 7% in some cases. Some of these high yielders also pay monthly. I highlight two of my favorite to buy today.
More Good News Ahead For REITs
07:05am, Monday, 23'rd Sep 2024
REITs have rebounded due to recent Fed rate cuts, despite previous struggles with rising interest rates and the pandemic's impact on commercial real estate. I believe further upside is in store for RE
Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
01:00am, Monday, 23'rd Sep 2024
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S Food and Drug Administ
Buffett-Style Investing: Finding Value In REITs
08:15am, Saturday, 21'st Sep 2024
Warren Buffett invests in companies that enjoy strong moats. A moat is a major competitive advantage. This can be applied to REITs. Here is how.
2 REITs That I Have Bought With An Intent To Hold Forever
01:20am, Saturday, 21'st Sep 2024
Many investors focus on selecting robust businesses with stable cash flows, reinvesting dividends to benefit from compounding, and avoiding the need for frequent trading. In the equity REIT segment, t
Two Dividend-Yielding REITs With Solid Upside Potential
10:00am, Thursday, 19'th Sep 2024
REITs are attractive for income investors due to their high dividend payouts, and office REITs, in particular, offer solid long-term upside as office activity could see an increase in 2025/2026. Kilro
Dividends Are Real Money: 3 Dividend-Paying REITs To Consider
07:00am, Thursday, 19'th Sep 2024
Dividends are crucial indicators of a company's financial health, providing real returns and reflecting profitability, as emphasized by Kelley Wright in "Dividends Still Don't Lie". EastGroup Properti
Agree Realty: Still Reasonably Valued For Its Rich Growth/Dividend Thesis - Initiate Buy
09:30am, Wednesday, 18'th Sep 2024
Agree Realty: Still Reasonably Valued For Its Rich Growth/Dividend Thesis - Initiate Buy
Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance
07:00am, Wednesday, 18'th Sep 2024
Daiichi Sankyo's ADCs, particularly trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan, are showing promising results in treating various cancers, including HER2-mutated NSCLC and HER2-positi
